$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
无BRCA突变的卵巢癌患者服用尼拉帕尼治疗效果怎么样?
2025-10-19 11:44:20
Check Details
卵巢癌患者服用奥拉帕尼治疗获得的生存期极其巨大
2025-10-19 11:44:20
Check Details
奥拉帕尼使卵巢癌患者获得三年以上无复发状况达到了50%
2025-10-19 11:44:20
Check Details
BRCA1基因缺陷的患者能够更好的在奥拉帕尼药效中获益
2025-10-19 11:44:20
Check Details
奥拉帕尼联合用药与单药的治疗效果
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗卵巢癌的安全性如何?
2025-10-19 11:44:20
Check Details
尼拉帕尼在高级别浆液性卵巢癌中的抗肿瘤活性
2025-10-19 11:44:20
Check Details
尼拉帕尼延长复发性卵巢癌无进展生存期
2025-10-19 11:44:20
Check Details
复发性卵巢癌治疗重大突破:尼拉帕尼延长铂类敏感型癌症的无进展生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼上市,国内卵巢癌患者的福音
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗复发性卵巢癌的长期获益
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗复发性卵巢癌患者
2025-10-19 11:44:20
Check Details
1
2
...
6850
6851
6852
6853
6854
6855
6856
...
10242
10243
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sparsentan Drug Interactions: Hypotension, Hyperkalemia, Renal Risk, CYP3A
2
How to Take Vigabatrin: Dosing and Vision Monitoring
3
Who Makes Belzutifan: Welireg and Merck/ MSD Explained
4
FDA Approves Infilbray for GD3 Neurological Symptoms
5
How to Take Selinexor: Dosing, Food, and Safety
6
FDA Approves Nelkarmi for ALK-TKI-Resistant NSCLC
7
FDA Approves Lembaz: First Therapy Shown to Extend Survival in Infantile-Onset NPC
8
Klygefa FDA Approval: Weekly Subcutaneous C5 Inhibition for AChR-Positive gMG
9
What Is Pralsetinib? RET-Positive Lung and Thyroid Cancer Explained
10
Sotorasib Diarrhea in NSCLC: Grading, Loperamide and Dose Adjustment
11
Avatrombopag vs Eltrombopag in ITP: Onset, Dosing Rules and Pre‑Procedure Use
12
Gilteritinib and Differentiation Syndrome in AML: Recognition, Emergency Management and Monitoring